Template:Second-generation BTKi table

Acalabrutinib Zanubrutinib Tirabrutinib Vecabrutinib LOXO-305 ARQ-531 BTK Bruton’s tyrosine mitogen-activated protein kinase kinase 1 Covalent, irreversible Covalent, irreversible Covalent, irreversible Non-covalent, reversible Non-covalent, reversible Non-covalent, reversible High Moderate High Moderate High Low N/A N/A N/A ITK N/A LYN, MEK1 II/III II/III I/II I/II I I

Novel BTK inhibitors in development for treatment of CLL

BTK inhibitor	BTK binding mechanism	Selectivity for BTK	Relevant non-BTK targets	Phase of clinical development
Table data